Dr. S. Venkatesan MD

JANUARY 17, 2025

While the numbers increase, still the debate between SAVR and TAVR is riddled with speculation, skepticism, and absolute confidence. Expected to improve with polymer valves) The latest trial to join the litereture is EARLY TAVR in October 2024 Here is a brief, personal comment about the paper for non-academic consumption.

TAVR 52

TAVR Aortic valve Hospital Academic 52

DAIC

MARCH 12, 2024

A cost-effectiveness analysis demonstrates the positive economic value of transcatheter aortic valve replacement (TAVR) using Evolut TAVR compared to surgical aortic valve replacement (SAVR) for low-risk patients. The findings showed a strong economic benefit of Evolut TAVR for low-risk patients from a U.S.

TAVR 52

TAVR Aortic valve Aortic Stenosis 52

Circulation: Cardiovascular Interventions

MARCH 26, 2025

Transcarotid transcatheter aortic valve replacement (TC-TAVR) has emerged as an alternative access in suboptimal transfemoral candidates, but no data exist comparing TC-TAVR and SAVR. At 30 days, the SAVR group showed a higher rate of the primary composite outcome compared with the TC-TAVR group (12.6% andP=0.001, respectively).

Aortic valve 40

Aortic valve Aortic Stenosis TAVR 40

Open Heart

JANUARY 19, 2023

Objective Postprocedural ischaemic and bleeding risks after transcatheter aortic valve replacement (TAVR) remain a major concern. We aimed to assess the accuracy of percutaneous coronary intervention (PCI)-derived models and the performance of a recalibrated model that included variables more applicable to TAVR.

Aortic valve 52

Aortic valve TAVR Aortic Myocardial Infarction 52

Journal of the American Heart Association

MARCH 21, 2025

The primary efficacy end point is the incidence of bleeding events, defined by the VARC3 (Valve Academic Research Consortium3) criteria, at 1year postrandomization. The primary safety end point is a composite of cardiac death, myocardial infarction, and ischemic stroke at 1 year.

Aortic valve 40

Aortic valve Aortic Myocardial Infarction TAVR 40

Cardiology Update

APRIL 9, 2024

SMART 4 ( NCT04722250 ) studied patients with severe aortic stenosis and a small aortic annulus who underwent transcatheter aortic valve replacement (TAVR). A total of 716 patients underwent TAVR with either a self-expanding supraannular valve or a balloon-expandable valve. vs. 6.2%) and stroke (2.9% vs. 4.7%) compared to SAVR.

Angina 52

Angina Myocardial Infarction Aortic valve Coronary Artery Disease 52